FANCD2 and chronic myelogenous leukemia, BCR-ABL1 positive: As per the objective of the study to find a common biomarker exclusively specific to AP-CML, NGS-based exome sequencing showed that the FANCD2 gene was mutated in all but one (59/60 = 98.3%) of the AP-CML patients but in none of the CP-CML patients or healthy controls (Supplementary Table S1: FANCD2 IGV).